title: Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
abstract: OBJECTIVE
  The combination of docetaxel and S-1 (DS) therapy is effective in patients with unresectable gastric cancer and is expected to be a regimen in neoadjuvant setting for advanced gastric cancer. This study was held to evaluate the efficacy and safety of DS followed by surgery.
  
  
  METHODS
  Patients with resectable gastric cancer received 2 courses of docetaxel 40 mg/m(2) on days 1, 15 and S-1 40 mg/m(2) bid orally on days 1-7, 15-21 every 4 weeks, followed by standard radical gastrectomy. Primary end point was the pathological response rate: rate of tumors in which one-third or more parts were affected.
  
  
  RESULTS
  Fourteen patients were enrolled. Thirteen (92.8 %) patients completed two courses of chemotherapy. Grade 3 adverse events were neutropenia in 3 (21.4 %) patients, anemia in 1 (6.2 %) patient and diarrhea in 1 (6.2 %) patient. There were no grade 4 adverse event and febrile neutropenia. All patients underwent R0 resection, and pathological response was found in 50.0 % of patients. There were no major surgical complications and no treatment-related mortality.
  
  
  CONCLUSIONS
  The neoadjuvant chemotherapy with DS was effective for patients with locally advanced gastric cancer with manageable toxicities. Further study to confirm the usefulness of this regimen is needed.
authors.affiliation: Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan, yokotaka1026@yahoo.co.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kosaka
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Akiyama
authors.forename: Hirochika
authors.initials: H
authors.lastname: Makino
authors.forename: Ryo
authors.initials: R
authors.lastname: Takagawa
authors.forename: Jun
authors.initials: J
authors.lastname: Kimura
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Ono
authors.forename: Chikara
authors.initials: C
authors.lastname: Kunisaki
authors.forename: Itaru
authors.initials: I
authors.lastname: Endo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D000077143:Docetaxel; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid